News
The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.
BofA notes that Novavax (NVAX) shares are up 21% after announcing the company has received communication from the FDA for a post marketing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results